PortfoliosLab logo
Catalyst Pharmaceuticals, Inc. (CPRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US14888U1016

CUSIP

14888U101

IPO Date

Nov 8, 2006

Highlights

Market Cap

$2.83B

EPS (TTM)

$1.31

PE Ratio

17.70

Total Revenue (TTM)

$393.23M

Gross Profit (TTM)

$327.56M

EBITDA (TTM)

$177.46M

Year Range

$14.47 - $26.16

Target Price

$34.00

Short %

8.06%

Short Ratio

5.34

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Catalyst Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


220.00%240.00%260.00%280.00%300.00%320.00%340.00%NovemberDecember2025FebruaryMarchApril
284.43%
298.72%
CPRX (Catalyst Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Returns By Period

Catalyst Pharmaceuticals, Inc. had a return of 12.36% year-to-date (YTD) and 59.74% in the last 12 months. Over the past 10 years, Catalyst Pharmaceuticals, Inc. had an annualized return of 20.83%, outperforming the S&P 500 benchmark which had an annualized return of 10.11%.


CPRX

YTD

12.36%

1M

-6.76%

6M

9.27%

1Y

59.74%

5Y*

36.21%

10Y*

20.83%

^GSPC (Benchmark)

YTD

-6.06%

1M

-3.27%

6M

-4.87%

1Y

9.44%

5Y*

14.30%

10Y*

10.11%

*Annualized

Monthly Returns

The table below presents the monthly returns of CPRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20258.10%1.46%5.94%-3.30%12.36%
2024-14.34%11.32%-0.56%-5.58%7.44%-4.21%11.30%17.46%-1.83%9.66%1.24%-5.44%24.15%
2023-16.72%-1.48%8.65%-3.98%-27.45%16.36%2.90%1.52%-16.74%6.16%16.28%16.49%-9.62%
2022-14.92%35.42%6.28%-8.08%-5.51%-2.64%46.08%32.23%-5.24%8.11%20.91%10.91%174.74%
20218.98%6.87%18.51%-0.65%20.74%3.98%1.57%-5.65%-3.81%11.32%18.64%-3.29%102.69%
20209.60%2.43%-8.55%23.12%-9.07%7.19%-6.93%-23.72%-9.45%-0.00%23.23%-8.74%-10.93%
201931.25%15.48%75.26%12.55%-39.02%9.71%29.95%23.45%-13.80%-10.92%-1.90%-19.18%95.31%
2018-13.30%-5.90%-25.08%17.15%37.14%-18.75%-7.37%16.61%12.17%-21.16%-14.93%-24.26%-50.90%
20176.67%0.89%72.57%-5.64%15.22%30.19%6.52%-6.46%-8.36%13.49%50.35%-9.07%272.38%
2016-24.08%-43.55%11.43%-41.88%-9.56%15.45%1.41%40.28%7.92%-3.67%3.81%-3.67%-57.14%
201522.90%3.01%15.16%-27.02%25.00%4.56%19.61%-26.52%-17.36%5.33%-14.08%-9.76%-17.51%
20140.00%14.87%0.89%-7.96%5.77%15.00%-10.28%40.97%3.75%-10.54%-10.77%12.08%52.31%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 90, CPRX is among the top 10% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of CPRX is 9090
Overall Rank
The Sharpe Ratio Rank of CPRX is 9191
Sharpe Ratio Rank
The Sortino Ratio Rank of CPRX is 8989
Sortino Ratio Rank
The Omega Ratio Rank of CPRX is 8585
Omega Ratio Rank
The Calmar Ratio Rank of CPRX is 9393
Calmar Ratio Rank
The Martin Ratio Rank of CPRX is 9393
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for CPRX, currently valued at 1.43, compared to the broader market-2.00-1.000.001.002.003.00
CPRX: 1.43
^GSPC: 0.46
The chart of Sortino ratio for CPRX, currently valued at 2.29, compared to the broader market-6.00-4.00-2.000.002.004.00
CPRX: 2.29
^GSPC: 0.77
The chart of Omega ratio for CPRX, currently valued at 1.26, compared to the broader market0.501.001.502.00
CPRX: 1.26
^GSPC: 1.11
The chart of Calmar ratio for CPRX, currently valued at 1.96, compared to the broader market0.001.002.003.004.005.00
CPRX: 1.96
^GSPC: 0.47
The chart of Martin ratio for CPRX, currently valued at 8.26, compared to the broader market-5.000.005.0010.0015.0020.00
CPRX: 8.26
^GSPC: 1.94

The current Catalyst Pharmaceuticals, Inc. Sharpe ratio is 1.43. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Catalyst Pharmaceuticals, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00NovemberDecember2025FebruaryMarchApril
1.43
0.46
CPRX (Catalyst Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Catalyst Pharmaceuticals, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-20.00%-15.00%-10.00%-5.00%0.00%NovemberDecember2025FebruaryMarchApril
-8.90%
-10.07%
CPRX (Catalyst Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Catalyst Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Catalyst Pharmaceuticals, Inc. was 94.25%, occurring on Nov 12, 2012. Recovery took 1717 trading sessions.

The current Catalyst Pharmaceuticals, Inc. drawdown is 8.90%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-94.25%Feb 2, 20071429Nov 12, 20121717Sep 10, 20193146
-64.87%Sep 12, 2019128Mar 16, 2020424Nov 17, 2021552
-45.37%Jan 17, 202392May 26, 2023330Sep 19, 2024422
-38.21%Nov 10, 200649Jan 24, 20075Jan 31, 200754
-28.72%Nov 18, 202148Jan 27, 202211Feb 11, 202259

Volatility

Volatility Chart

The current Catalyst Pharmaceuticals, Inc. volatility is 14.53%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%NovemberDecember2025FebruaryMarchApril
14.53%
14.23%
CPRX (Catalyst Pharmaceuticals, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Catalyst Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Catalyst Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio
20.040.060.080.0100.0
CPRX: 17.7
The chart displays the Price-to-Earnings (P/E) ratio for CPRX, comparing it with other companies in the Biotechnology industry. Currently, CPRX has a P/E ratio of 17.7. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
2.04.06.08.010.0
CPRX: 0.0
The chart shows the Price/Earnings to Growth (PEG) ratio for CPRX compared to other companies in the Biotechnology industry. CPRX currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
20.040.060.080.0100.0
CPRX: 5.8
This chart shows the Price-to-Sales (P/S) ratio for CPRX relative to other companies in the Biotechnology industry. Currently, CPRX has a P/S ratio of 5.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
2.04.06.08.010.0
CPRX: 3.9
The chart illustrates the Price-to-Book (P/B) ratio for CPRX in comparison with other companies in the Biotechnology industry. Currently, CPRX has a P/B value of 3.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items